-
Ascendis Pharma files patent for ocular drug delivery system using cross-linked Ha
22 Mar 2024 14:59 GMT
… on Ascendis Pharma, Nanoparticle drug conjugates was a key … a VEGF antagonist like ranibizumab in the form of a … ocular indications targeted by the treatment, including neovascular diseases, … using the disclosed HA drug conjugate and administration method, …
-
Beyond Step Edits: Treatment Strategy After Bevacizumab in nAMD
21 Mar 2024 14:50 GMT
… at Stanford University School of Medicine. Dr. Rahimy explores various … various agents like aflibercept or ranibizumab.
Another scenario entails encountering … discusses patient preferences for shorter treatment intervals despite favorable outcomes, …
-
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
21 Mar 2024 02:05 GMT
… drugs, with the sale of Cimerli (a Lucentis biosimilar containing ranibizumab … ) and bevacizumab in future trials. Financial Overview CHRS reported … loans on the balance sheet. Biotech Beast comments on CHRS, … -114, due from a trial in solid tumors in H1 …
-
RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study
29 Mar 2024 01:28 GMT
… eligibility criteria. The trial’s primary outcome … trial, 42 participants met the required anatomic response to intravitreal ranibizumab … the treatment of nAMD further. Two pivotal trials, … Food and Drug Administration (FDA) and European Medicines Agency (EMA …
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
19 Mar 2024 10:11 GMT
… commercializes high quality medicines for the treatment of cancer, … so that first-rate pharmaceutical drugs can become widely accessible … phase 3, non-inferiority trials. Lancet. 399,10326 ( … Seven-year outputs in ranibizumab-treated patients in ANCHOR …
-
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18 Mar 2024 11:05 GMT
… all phases of ophthalmic drug development.
George Lasezkay, … trials as principal investigator, including the development of ranibizumab … for clinical development and medical affairs in ophthalmology. … suspension), for the treatment of neovascular age-related …
-
New eye drops found safe and effective in diabetic retinopathy and diabetic macular edema in New trial
13 Mar 2024 21:11 GMT
… Ib/IIa trial randomised 13 treatment-naïve mild diabetic … of EXN407. Rescue medication (standard of care, ranibizumab or aflibercept) was … with no major or serious drug-related safety concerns. EXN407 … minimal risk of adverse drug reactions in non-ocular …
-
Sandoz completes acquisition of ranibizumab biosimilar
04 Mar 2024 20:38 GMT
… of Cimerli, a ranibizumab biosimilar, from Coherus BioSciences … is interchangeable with Lucentis (ranibizumab, Genentech), is indicated for … affordable and much-needed medicines,” Keren Haruvi, president … now offer even more treatment options for U.S …
-
Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration
23 Feb 2024 08:30 GMT
… of bevacizumab and ranibizumab, respectively.11, … ELISA) kit (Elabscience Biotechnology, China), paraformaldehyde … the Second Military Medical University (Shanghai, … pharmaceutics11090460
17. Wong CW, Wong TT. Posterior segment drug delivery for the treatment …
-
Interleukin-8 Promoter Polymorphism −251 A/T and Treatment Response in Neovascular Age-related Macular Degeneration
21 Feb 2024 08:21 GMT
… , Denmark; 2Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen … ranibizumab, as this study was conducted in a transitional period of treatment … need for personalized medicine and new therapeutic targets in treatment for nAMD …